Group 1 - The Qingdao Municipal People's Congress is actively contributing to the city's development plans during its 17th session [1] - The "China Health Bay" construction plan aims to integrate healthcare with tourism and wellness, focusing on comprehensive health services for all ages [3] - The Qingdao Eye Hospital's resources align with the strategic needs of the "China Health Bay" initiative, emphasizing the transformation of specialized advantages into regional development benefits [3] Group 2 - The plan includes the establishment of a clinical research hospital on a 26.8-acre site, focusing on ophthalmology and integrating clinical research with healthcare services [4] - A comprehensive ecosystem for medical education, research, and industry is proposed, aiming to attract related enterprises and create a complete industrial chain [4] - The initiative seeks to foster collaboration with universities and research institutions to develop replicable models for integrated development, enhancing the "China Health Bay" as a leading health industry hub [4]

朝聚眼科(02219)发布公告，于2026年1月20日该公司斥资16.06万港元回购6万股，回购价格为每股2.64- 2.70港元。 ...

Core Viewpoint - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Buyback Details - The company will repurchase 60,000 shares at a total cost of HKD 160,600 [1] - The buyback price ranges from HKD 2.64 to HKD 2.70 per share [1] - The buyback is scheduled for January 20, 2026 [1]

格隆汇1月20日丨朝聚眼科(02219.HK)公告，1月20日耗资16.1万港元回购6万股，每股回购价2.64-2.7港 元。 ...

Group 1 - The core point of the article is the announcement of a share reduction plan by the fourth largest shareholder, Advanced Manufacturing Fund, for He Shi Eye Hospital, which is set to take place from February 7, 2026, to May 6, 2026, involving a maximum reduction of 3.1061 million shares, accounting for 1.97% of the total share capital [1] - There has been a significant management change at He Shi Eye Hospital, with the chairman's son taking over as general manager and the company secretary resigning in December 2025 [1] - Since its listing in 2022, several fundraising projects of He Shi Eye Hospital have not met expected returns or progress targets [1] Group 2 - As of January 20, 2026, He Shi Eye Hospital's closing price was 21.51 yuan, giving it a market capitalization of approximately 3.399 billion yuan [1] - If the Advanced Manufacturing Fund reduces its holdings at the price of 21.51 yuan, it would realize over 66 million yuan in cash [1]

爱尔眼科1月20日大宗交易平台出现一笔成交，成交量18.00万股，成交金额203.94万元，大宗交易成交 价为11.33元，相对今日收盘价溢价0.09%。该笔交易的买方营业部为华泰证券股份有限公司成都锦晖西 二街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证券营业部。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为5580.13万元。 1月20日爱尔眼科大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 18.00 | 203.94 | 11.33 | 0.09 | 华泰证券股份有限公司成 | 华泰证券股份有限公司成 | | | | | | 都锦晖西二街证券营业部 | 都锦晖西二街证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，爱尔眼科今日收盘价为11.32元，下跌0.09%，日换手率为0.71%，成交额为 6.42亿元，全天 ...

Core Viewpoint - The "domestically produced all-laser refractive surgery machine" developed by Professor Zhang Mingchang's team has been recognized as one of the "Top Ten Original Advances in Ophthalmology in China for 2025," marking a significant breakthrough in the field of high-end laser treatment equipment for myopia refractive surgery in China [1][7]. Group 1: Research and Development Achievements - Professor Zhang Mingchang's team has been dedicated to the innovation and research of ocular surface diseases and refractive treatment technologies [3][9]. - The team previously developed the "tear lipid content detection test strip," which was included in the "Top Ten Advances in Chinese Ophthalmology" in 2021 [3][9]. Group 2: Technological Breakthroughs - The newly developed device achieves significant technological breakthroughs in laser energy control, beam positioning accuracy, and surgical process stability, specifically designed for myopia refractive surgery [5][11]. - The core optical system and intelligent control platform of the device are entirely developed domestically, breaking the long-standing reliance on imported equipment [5][11]. Group 3: Market Impact and Future Prospects - The device is expected to provide higher quality and more accessible high-end refractive surgery options for myopia patients, potentially lowering surgical costs and benefiting many individuals seeking vision correction [5][11]. - The development and transformation of this achievement exemplify successful collaboration between medical engineering and industry-academia partnerships, promoting the localization of high-end ophthalmic treatment equipment and supporting the self-control and technological upgrades of the related industry chain [12]. - Looking ahead, the team plans to deepen collaboration with the industry to promote more original and leading technologies for clinical application, contributing to the high-quality development of eye health in China and supporting the "Healthy China" strategic goal [14].

证券日报网讯 1月19日，爱尔眼科在互动平台回答投资者提问时表示，公司高度重视，加强融合，持续 推进技术创新、服务创新，为全年龄段人群提供多层次的全眼科医疗服务。 （文章来源：证券日报） ...

戴鸿斌院长强调，成人斜视手术不仅是为了改善外观，更关乎视功能的重建。"许多成人患者因斜视出 现复视、视疲劳甚至头痛，长期如此会影响工作效率与生活质量。因此，一旦发现斜视频率增加或伴有 相关视觉症状，应及早就诊，接受专业评估。" 3岁时，小李首次接受斜视矫正手术，后因斜视复发在7岁时进行二次矫正。成年后，随着工作压力增 大，他的左眼开始出现"间隙性"外斜——每当熬夜加班、睡眠不足或长时间面对电脑，左眼便不受控制 地跑偏。这不仅严重影响外观形象，更渐渐侵蚀着他的职业自信，甚至让他对人际交往和未来规划产生 焦虑。 为了彻底摆脱这一困扰，在新疆电力系统工作的他，毅然决定返回家乡湖北武汉寻求诊治。经过多方咨 询，他了解到武汉华厦眼科医院戴鸿斌院长在复杂成人斜视矫正领域经验丰富，尤其擅长运用微创技术 实现精准矫正，手术复发率低。 "小李属于共同性内斜视，这与长期疲劳用眼导致的眼睛协调功能下降密切相关。"武汉华厦眼科戴鸿斌 院长分析道。更棘手的是，由于小李的眼部已经接受过两次手术，眼肌结构可能已有粘连、疤痕形成或 肌力失衡，这大大增加了第三次手术的难度与风险。"既往手术会改变眼部解剖结构，肌肉与周围组织 关系复杂，再次手术 ...

Core Insights - Nova Eye Medical reported a record quarter for December 2025, highlighting strong performance and growth potential [1] Performance Highlights - The company emphasized the significance of the quarterly sales results, indicating a successful period for its operations [1] - The presentation included a discussion on the factors that contributed to the record sales performance [1] Future Outlook - The Managing Director, Tom Spurling, is set to provide insights into potential sales performance and the outlook for the upcoming year [2]